Compare Aterian Inc (ATER) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aterian Inc vs Crispr Therapeutics AG — how do they compare? Aterian Inc trades at $0.49 (market cap $5.32M), while Crispr Therapeutics AG trades at $53.85 (market cap $5.23B). The key difference: Crispr Therapeutics AG is far larger — about 983.1× Aterian Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Aterian Inc nearer its low. Which is the better fit depends on your goals.
| ATER | CRSP | |
|---|---|---|
Market Cap | $5.32M | $5.23B |
Sector | Consumer Cyclical | Health |
52-Week High | $1.39 | $76.78 |
52-Week Low | $0.36 | $44.34 |
Enterprise Value | $5.90M | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aterian (ATER) trades at $0.48, down 2.72% on the day, with a bearish technical signal. The company reported a net loss of -$18.98M in 2025, though it has beaten EPS estimates in recent quarters. Recent news highlights a pending asset sale that could return $0.85–$1.14 per share to stockholders, subject to a special meeting vote.
The outlook hinges on the asset sale approval, offering potential upside, but ongoing operational losses and negative cash flow pose significant risks. Analyst sentiment is split evenly between Buy and Hold, reflecting uncertainty around the company's restructuring and future profitability.
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aterian Inc
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
